

Supplemental Figure for:
Analysis of the role of plasma 25hydroxyvitamin D levels in survival outcomes in patients from phase III MPACT trial of metastatic pancreatic cancer
Daniel Von Hoff et al.

Supplemental Figure 1. CONSORT diagram of patients in the current analysis. ^a One patient randomized to gemcitabine (Gem) was treated with *nab*-paclitaxel (*nab*-P) plus Gem. In the intent-to-treat analysis, this patient was categorized as randomized. In all analyses of the treated population, this patient was categorized as treated. 25(OH)D, 25-hydroxyvitamin D.

